Bone remodelling is a strictly regulated dynamic process between bone resorption and bone formation.
Many factors are involved in the process and affect the dynamic balance. Inflammation-mediated bone loss is a
major feature of various bone diseases, including periodontitis, rheumatoid arthritis (RA) and spondyloarthritis
(SpA). Interleukin-17 (IL-17) plays an important role in inflammatory bone disease and could be an attractive
therapeutic target. This review focuses on the osteoclastic effects of IL-17 in different cell types and summarizes
the current knowledge of IL-17 signalling pathways. Typical IL-17–mediated bone destruction disorders are
examined. The review also provides an overview of possible strategies for therapeutic intervention for inflammatory
loss of bone targeting IL-17.
Keywords: IL-17, IL-17 receptor, bone loss, osteoclastogensis, RANKL, osteoclasts.
Rights & PermissionsPrintExport